Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification
Walter Ling, Ph.D. Lead Investigator Director, Integrated Substance Abuse Programs, UCLA 11075 Santa Monica Boulevard Suite 225 Los Angeles, CA 90025 lwalter@ix.netcom.com

For decades clinicians have been frustrated by the inability to successfully detoxify opiate addicted patients because opiate-based detoxification, one of the most effective means to achieving that goal, has been unavailable outside the very restrictive confines of narcotic treatment programs (NTPs). A new medication, Buprenorphine, shows promise as an effective aid for opiate detoxification. However, little data have been generated for the shorter-term use of Buprenorphine/Naloxone (Suboxone) for this indication. Since the diversity of clinics in the CTN provides an unparalleled opportunity to conduct such a clinical endeavor, the utility of Buprenorphine/Naloxone in short term (13 day) detoxification in inpatient settings will be tested in the CTN.

Primary Findings: A total of 59 of the 77 (77%) inpatients assigned to the Buprenorphine/Naloxone condition achieved the treatment success criterion compared to only 8 of the 36 (22%) assigned to clonidine. The study supported the benefits of Buprenorphine/Naloxone for opioid detoxification in inpatient treatment programs and illustrated important ways in which clinical research can be conducted in community treatment programs.

Primary Outcomes Paper: Ling W, et al. A Multi-Center Randomized Trial of Buprenorphine-Naloxone versus Clonidine for Opioid Detoxification: Findings for the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005;100:1090-1110. [more. . .]

LATEST PUBLICATIONS AND DATA

	Find all publications in the Library about Protocol CTN-0001
	Researchers: Data from this protocol is available from CTN Public Datashare